Literature DB >> 21294996

Relationship between daily dose, plasma concentrations, dopamine receptor occupancy, and clinical response to quetiapine: a review.

Anna Sparshatt1, David Taylor, Maxine X Patel, Shitij Kapur.   

Abstract

OBJECTIVE: To assess the relationships among quetiapine blood concentration, daily dose, dopamine receptor occupancy, and clinical outcome in order, if possible, to define a target plasma level range in which therapeutic response is enhanced and adverse events are minimized. DATA SOURCES: A search of the database Embase from 1974 to March 2009 and the databases MEDLINE and PubMed from 1966 to March 2009 was conducted. The drug name quetiapine was searched with each of the terms plasma levels, plasma concentration, therapeutic drug monitoring, and dopamine occupancy. STUDY SELECTION: The search uncovered 42 relevant articles. All published reports of quetiapine plasma or serum concentration were considered for inclusion if reported in relation to a dose, clinical outcome, or dopamine occupancy. After application of exclusion criteria, 20 articles remained. DATA EXTRACTION: Trials designed primarily to investigate an interaction between quetiapine and another medication were excluded, as were those designed to compare methods of blood sample analysis. DATA SYNTHESIS: There was a weak correlation between quetiapine dose and measured plasma concentration (from trough samples). Quetiapine dose was correlated with central dopamine D(2) occupancy, although the relationship between plasma level and D(2) occupancy is less clear.
CONCLUSIONS: The dose-response relationship for (immediate-release) quetiapine is established. Data on plasma concentration-response relationships are not sufficiently robust to allow determination of a therapeutic plasma level range for quetiapine. Therapeutic drug monitoring procedures are thus probably not routinely useful in optimizing quetiapine dose. Further examination of the relationship between peak quetiapine plasma concentration and clinical response is necessary. © Copyright 2011 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21294996     DOI: 10.4088/JCP.09r05739yel

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  11 in total

Review 1.  Comparative effectiveness of atypical antipsychotics in schizophrenia: what have real-world trials taught us?

Authors:  Azizah Attard; David M Taylor
Journal:  CNS Drugs       Date:  2012-06-01       Impact factor: 5.749

2.  Tropisetron enhances recognition memory in rats chronically treated with risperidone or quetiapine.

Authors:  Indrani Poddar; Patrick M Callahan; Caterina M Hernandez; Xiangkun Yang; Michael G Bartlett; Alvin V Terry
Journal:  Biochem Pharmacol       Date:  2017-11-24       Impact factor: 5.858

3.  Treatment of first-episode non-affective psychosis: a randomized comparison of aripiprazole, quetiapine and ziprasidone over 1 year.

Authors:  Benedicto Crespo-Facorro; Victor Ortiz-Garcia de la Foz; Ignacio Mata; Rosa Ayesa-Arriola; Paula Suarez-Pinilla; Elsa M Valdizan; Obdulia Martinez-Garcia; Rocío Pérez-Iglesias
Journal:  Psychopharmacology (Berl)       Date:  2014-01       Impact factor: 4.530

4.  Correlation of hair risperidone concentration and serum level among patients with schizophrenia.

Authors:  Xiujia Sun; Lihua Wang; Fuzhong Yang; Juanjuan Ren; Ping Jiang; Hongmei Liu; Huafang Li; Chunbo Li; Chen Zhang
Journal:  Gen Psychiatr       Date:  2019-02-20

Review 5.  Clozapine and therapeutic drug monitoring: is there sufficient evidence for an upper threshold?

Authors:  Gary Remington; Ofer Agid; George Foussias; Larissa Ferguson; Krysta McDonald; Valerie Powell
Journal:  Psychopharmacology (Berl)       Date:  2012-11-22       Impact factor: 4.530

6.  Plasma quetiapine in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 2000-2011.

Authors:  Simon A Handley; Sally V J Bowskill; Maxine X Patel; Robert J Flanagan
Journal:  Ther Adv Psychopharmacol       Date:  2013-06

7.  Quetiapine in refractory hyperactive and mixed intensive care delirium: a case series.

Authors:  Ruth Y Y Wan; Moneesha Kasliwal; Catherine A McKenzie; Nicholas A Barrett
Journal:  Crit Care       Date:  2011-06-28       Impact factor: 9.097

Review 8.  Current Data on and Clinical Insights into the Treatment of First Episode Nonaffective Psychosis: A Comprehensive Review.

Authors:  Benedicto Crespo-Facorro; Jose Maria Pelayo-Teran; Jacqueline Mayoral-van Son
Journal:  Neurol Ther       Date:  2016-08-23

9.  Anti-N-Methyl-D-Aspartate Receptor Encephalitis: A New Challenging Entity for Consultation-Liaison Psychiatrist.

Authors:  G E Maccaferri; A O Rossetti; J Dalmau; A Berney
Journal:  Brain Disord Ther       Date:  2016-05-10

10.  Evaluation of the use of low-dose quetiapine and the risk of metabolic consequences: A retrospective review.

Authors:  Chelsea N Carr; Shruti Lopchuk; Mary E Beckman; Terrence Bradley Baugh
Journal:  Ment Health Clin       Date:  2016-11-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.